Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine

  1. Jennifer M. Polinski
  2. Andrew R. Weckstein
  3. Michael Batech
  4. Carly Kabelac
  5. Tripthi Kamath
  6. Raymond Harvey
  7. Sid Jain
  8. Jeremy A. Rassen
  9. Najat Khan
  10. Sebastian Schneeweiss
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Importance

Vaccination against the SARS-CoV-2 virus is critical to control the pandemic. Randomized trials demonstrated efficacy of the single-dose Ad26.COV2.S COVID vaccine but data on longer-term protection in clinical practice and effectiveness against variants are needed.

Objective

To assess the effectiveness of Ad26.COV2.S in preventing COVID infections and COVID-related hospitalizations in clinical practice, the longer-term stability of its protective effect and effectiveness against Delta variants.

Design

Cohort study of newly Ad26.COV2.S-vaccinated and unvaccinated individuals.

Setting

U.S. insurance claims data through July 2021.

Participants

Individuals 18 years and older newly vaccinated with Ad26.COV2.S and up to 10 unvaccinated individuals matched exactly by age, sex, date, location, comorbidity index plus 17 COVID-19 risk factors via propensity score (PS) matching.

Intervention

Vaccination with Ad26.COV2.S versus no vaccination.

Main outcomes

We estimated vaccine effectiveness (VE) for observed COVID-19 infection and COVID-19-related hospitalization, nationwide and stratified by age, immunocompromised status, calendar time, and states with high incidence of the Delta variant. We corrected VE estimates for under-recording of vaccinations in insurance data.

Results

Among 390,517 vaccinated and 1,524,153 matched unvaccinated individuals, VE was 79% (95% CI, 77% to 80%) for COVID-19 and 81% (79% to 84%) for COVID-19-related hospitalizations. VE was stable over calendar time. Among states with high Delta variant incidence, VE during June/July 2021 was 78% (73% to 82%) for infections and 85% (73% to 91%) for hospitalizations. VE for COVID-19 was higher in individuals <50 years (83%; 81% to 85%) and lower in immunocompromised patients (64%; 57% to 70%). All estimates were corrected for under-recording; uncorrected VE was 69% (67% to 71%) and 73% (69% to 76%), for COVID-19 and COVID-19-related hospitalization, respectively.

Conclusions

These non-randomized data across U.S. clinical practices show high and stable vaccine effectiveness of Ad26.COV2.S over time before the Delta variant emerged to when the Delta variant was dominant.

Related articles

Related articles are currently not available for this article.